VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | Highlights from SABCS 2020

Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, discussing ongoing breast cancer clinical trials, including the ADAPT trial (NCT01779206), RxPONDER trial (NCT01272037), and DESTINY-Breast01 (NCT03248492) which suggest high clinical response rates and could reduce the need for chemotherapy in 60% of early breast cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter